{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:57:07Z","timestamp":1790870227688,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1245\/s10434-026-20252-9","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:51:39Z","timestamp":1785761499000},"page":"9913-9918","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recurrence in Real Time: Rethinking Breast Cancer Follow-Up Evaluation with Circulating Tumor DNA"],"prefix":"10.1245","volume":"33","author":[{"given":"Nicole","family":"Taylor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"York Lin","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian Sheng","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Alexander","family":"Palesty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Sieling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Sookhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"20252_CR1","unstructured":"American Cancer Society. Cancer Facts & Figures 2026. (n.d.). Retrieved xxxs at https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/2026-cancer-facts-figures.html."},{"key":"20252_CR2","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1007\/s11845-022-02926-x","volume":"191","author":"D Courtney","year":"2022","unstructured":"Courtney D, Davey MG, Moloney BM, Barry MK, Sweeney K, McLaughlin RP, et al. Breast cancer recurrence: factors impacting occurrence and survival. Ir J Med Sci. 2022;191:2501\u201310. https:\/\/doi.org\/10.1007\/s11845-022-02926-x.","journal-title":"Ir J Med Sci."},{"key":"20252_CR3","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","volume":"378","author":"C Davies","year":"2011","unstructured":"Davies C, Godwin J, Gray R,  Early Breast Cancer Trialists\u2019 Collaborative Group, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771\u201384.","journal-title":"Lancet"},{"key":"20252_CR4","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1056\/nejmoa1701830","volume":"377","author":"H Pan","year":"2017","unstructured":"Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, et al. 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377:1836\u201346. https:\/\/doi.org\/10.1056\/nejmoa1701830.","journal-title":"N Engl J Med."},{"key":"20252_CR5","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/1097-0142(19910801)68:3<574::AID-CNCR2820680322>3.0.CO;2-B","volume":"68","author":"F Safi","year":"1991","unstructured":"Safi F, Kohler I, Beger H-G, R\u00f6ttinger E. The value of the tumor marker CA15-3 in diagnosing and monitoring breast cancer: A comparative study with carcinoembryonic antigen. Cancer. 1991;68:574\u201382. https:\/\/doi.org\/10.1002\/1097-0142(19910801)68:3%3c574::AID-CNCR2820680322%3e3.0.CO;2-B.","journal-title":"Cancer."},{"key":"20252_CR6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.breast.2020.05.005","volume":"52","author":"JX Hing","year":"2020","unstructured":"Hing JX, Mok CW, Tan PT, Sudhakar SS, Seah CM, Lee WP, Tan SM. Clinical utility of tumour marker velocity of cancer antigen 15\u20133 (CA 15\u20133) and carcinoembryonic antigen (CEA) in breast cancer surveillance. Breast. 2020;52:95\u2013101. https:\/\/doi.org\/10.1016\/j.breast.2020.05.005.","journal-title":"Breast."},{"key":"20252_CR7","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nrc.2017","volume":"17","author":"JCM Wan","year":"2017","unstructured":"Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17:223\u201338. https:\/\/doi.org\/10.1038\/nrc.2017.","journal-title":"Nat Rev Cancer."},{"key":"20252_CR8","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1373\/clinchem.2016.260331","volume":"62","author":"F Leung","year":"2016","unstructured":"Leung F, Kulasingam V, Diamandis EP, Hoon DS, Kinzler K, Pantel K, Alix-Panabi\u00e8res C. Circulating tumor DNA as a cancer biomarker: fact or fiction? Clin Chem. 2016;62:1054\u201360. https:\/\/doi.org\/10.1373\/clinchem.2016.260331.","journal-title":"Clin Chem."},{"key":"20252_CR9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1158\/2767-9764.CRC-24-0234","volume":"6","author":"PH Lin","year":"2026","unstructured":"Lin PH, Tsai LW, Lo C, Kuo SH, Ni CC, Yu CH, Huang CS. ctDNA detected after neoadjuvant therapy for HER2-positive breast cancer is associated with inferior outcomes and may inform adjuvant therapy. Cancer Res Commun. 2026;6:105\u201314. https:\/\/doi.org\/10.1158\/2767-9764.CRC-24-0234.","journal-title":"Cancer Res Commun."},{"key":"20252_CR10","doi-asserted-by":"publisher","first-page":"e2300456","DOI":"10.1200\/PO.23.00456","volume":"8","author":"JA Shaw","year":"2024","unstructured":"Shaw JA, Page K, Wren E, de Bruin EC, Kalashnikova E, Hastings R, et al. Serial postoperative circulating tumor DNA assessment has strong prognostic value during long-term follow-up in patients with breast cancer. JCO Precis Oncol. 2024;8:e2300456. https:\/\/doi.org\/10.1200\/PO.23.00456. (Erratum in JCO Precis Oncol. 2024, 8(e2400310), pp. 10.1200\/PO.24.00310).","journal-title":"JCO Precis Oncol."},{"key":"20252_CR11","doi-asserted-by":"publisher","first-page":"851","DOI":"10.2147\/BCTT.S542704","volume":"17","author":"Y Lu","year":"2025","unstructured":"Lu Y, Ren L, Yang M, Liu J. Clinical management of circulating tumor DNA in breast cancer: detection, prediction, and monitoring. Breast Cancer. 2025;17:851\u201361. https:\/\/doi.org\/10.2147\/BCTT.S542704.","journal-title":"Breast Cancer."},{"key":"20252_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102914","volume":"58","author":"AA Davis","year":"2020","unstructured":"Davis AA, Jacob S, Gerratana L, et al. Landscape of circulating tumour DNA in metastatic breast cancer. EBioMedicine. 2020;58:102914. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102914.","journal-title":"EBioMedicine."},{"key":"20252_CR13","doi-asserted-by":"publisher","first-page":"LBA507","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA507","volume":"42","author":"Sherene Loi","year":"2024","unstructured":"Loi Sherene, et al. Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2\u2013, node-positive, high-risk early breast cancer (EBC). J Clin Oncol. 2024;42:LBA507\u2013LBA507. https:\/\/doi.org\/10.1200\/JCO.2024.42.17_suppl.LBA507.","journal-title":"J Clin Oncol."},{"key":"20252_CR14","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.annonc.2022.11.005","volume":"34","author":"NC Turner","year":"2023","unstructured":"Turner NC, Swift C, Jenkins B, Kilburn L, Coakley M, Beaney M, et al. c-TRAK TN investigators. Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer. Ann Oncol. 2023;34:200\u201311. https:\/\/doi.org\/10.1016\/j.annonc.2022.11.005.","journal-title":"Ann Oncol."},{"issue":"Suppl 1","key":"20252_CR15","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1016\/j.ejon.2004.06.006","volume":"8","author":"H Mars\u00e9","year":"2004","unstructured":"Mars\u00e9 H, Van Cutsem E, Grothey A, Valverde S. Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda). Eur J Oncol Nurs. 2004;8(Suppl 1):S16-30. https:\/\/doi.org\/10.1016\/j.ejon.2004.06.006.","journal-title":"Eur J Oncol Nurs."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20252-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20252-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20252-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:17:49Z","timestamp":1790867869000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-20252-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["20252"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20252-9","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"assertion":[{"value":"23 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflicts of interest.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}}]}}